Amgen Inc. / Kite Pharma, Inc.

Hematologic and Solid Tumor Malignancies (CAR-T Immunotherapy)

$6.0B Global CAR-T market 2025 ($6.03B)

Disease Overview

Chimeric antigen receptor (CAR) T cell therapy reprograms a patient's own T cells with a synthetic receptor against a tumor antigen, then reinfuses them as a 'living drug.' CD19-targeted CAR-Ts deliver durable remissions in B-cell leukemias and lymphomas; expansion to solid tumors and other hematologic targets remains a major unmet need.

Competitive Landscape

In early 2015 the CAR-T field was a three-horse race ahead of approvals: Novartis–UPenn (CTL019/tisagenlecleucel, later Kymriah), Kite Pharma (KTE-C19, later Yescarta/axicabtagene ciloleucel) and Juno Therapeutics (JCAR017, later Breyanzi after Bristol-Myers Squibb's $9B Celgene acquisition). Bluebird and Celgene were partnering on bb2121 (later Abecma) in multiple myeloma. Amgen had no internal CAR-T platform but possessed a deep oncology target portfolio (notably BCMA, FLT3, mesothelin and others), making the Kite alliance a fast on-ramp to next-generation CAR constructs. The deal gave Kite $60M upfront, R&D funding through IND, and up to $525M in milestones per program (each direction), with tiered royalties — high single- to double-digit on Amgen-program sales and single-digit on Kite-program sales. The deal mattered because it validated CAR-T as a platform modality for big pharma and surfaced novel target classes beyond CD19. Strategic context shifted in October 2017 when Gilead acquired Kite for $11.9B, eclipsing the Amgen relationship; Yescarta later became the leading CAR-T product by share, while the joint Amgen-Kite programs did not produce a publicly disclosed launched asset.